



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

# Overview of EMA's interaction with patients and consumers organisations (2013)

---

Presented by: Nathalie Bere  
Stakeholders and Communication Division

An agency of the European Union






## Introduction

- Quantitative overview of EMA activities where patients, consumers and their organisations have been involved throughout 2013
- Provides comparison to preceding years
- Will be included within the annual report for 2013, presented to the EMA Management Board and published on EMA website in 2014
- High level of interaction between EMA and PCOs achieved during 2013




**Overall number of patient & consumer involvement in EMA activities**  
2007–2013





### Comparison of involvement in core activities 2009–2013






## **Activities are split into three categories;**

1. activities in which patients/consumers are members, alternates or observers,
2. activities involving individual patient experts, and
3. activities requiring organisation representatives.



**Comparison of involvement as committee/WP members, experts and representatives of organisations**  
2007–2013





### **Members of committees /working parties:**

**MB:** 2 members, **COMP:** 2 members, **PDCO:** 3 members and 3 alternates.

**CAT:** 2 members and 2 alternates. **PRAC** 1 member, 1 alternate.

**HCPWP:** 2 observers.

### **Experts:**

333 experts were involved in Agency activities during 2013:

- SAG/ad-hoc expert meetings; 33 representatives (22 meetings);
- SA meetings; 28 representatives (now includes SA);
- PRAC consultations x 2 (8 Patient representatives);
- Review of package leaflets (110);
- Review of safety communications; (39);
- Review of EPAR summaries (48);
- Participation in EMA annual training session (63)



## **Representatives:**

163 representatives of organisations were involved during 2013:


- CHMP consultation
- Pharmacovigilance legislation forum
- Working groups (e.g. funding of organisations, EudraCT)
- Ad-hoc observers attending PCWP meetings
- Workshops






### Package leaflets and EPAR summaries sent for review

2007–2013





**Percentage of package leaflets and EPAR summaries reviewed**  
2007–2013






## Eligible Organisations

- There are 36 eligible patient/consumer organisations working with the Agency. During 2013, 3 new organisations became eligible.

Review of eligibility of organisations  
2013





## EMA Working Party with Patients & Consumers Organisations (PCWP)

The PCWP continues to play a key role in the interaction between the EMA and PCOs.

- 19 members and 18 alternates representing PCOs;
- 6 members from the EMA Scientific Committees;
- 1 member from the EMA secretariat;
- Observers from the CMD-h, HCP WP and MB.

Four PCWP meetings held during 2013; one with all 'eligible' organisations, two joint with the Healthcare Professionals' Working Party (HCP WP) and one-day training session.



## **PCWP representatives involved in many EU-wide initiatives**

- The European Network of Paediatric Research (Enpr-EMA); patient representative member of the Enpr-EMA coordinating group
- The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP); PCO representative member of the steering group
- The Pharmacoepidemiological Research on Outcomes of Therapeutics (PROTECT); patient representatives are involved in the PROTECT consortium



## Activities involving patients and consumers during 2013:

Increased involvement in **benefit / risk** evaluations

- **CHMP & PRAC consultations:** specific consultations with PCOs on medicines / issues under evaluation
- **SAG/expert meetings** - 33 patients participated as patient experts in 22 meetings - have provided unique information in terms of real life experiences and views.
- **Scientific Advice Working Party** – 28 patients' representatives participated as experts in specific scientific advice requests (16 for protocol assistance (orphan drugs).



## Activities related to the implementation of the new pharmacovigilance legislation

- **1 stakeholder meeting** (including industry, patient/consumer and healthcare professional representatives, national medicines regulatory authorities and the European Commission)
- **Additional monitoring of medicines** & direct patient reporting - impact on the package leaflet; PCOs extensively consulted on the black symbol and related text and launch



## Involvement in EMA workshops/conferences

- Workshop on Conflicts of Interest Policy
- Clinical Trial advisory groups
- Workshop on medication errors
- Workshop on patient support and market research programmes
- Workshop on medicines shortages
- Workshop on the patient voice in benefit-risk assessment
- Workshop on clinical investigation of medicines for multiple sclerosis
- Workshop on biosimilars
- Workshop on Antimicrobial Resistance (AMR)





## Conclusion

- The involvement of PCOs continues to be extremely beneficial;
- They are a recognised and integral part of the Agency's work
- With the passing years, their involvement continues to increase and expand, but also evolves ensuring it occurs in the most optimal manner possible.
- This collaborative interaction allows patients to engage with the EMA to share their real-life experiences and in doing so, they provide valuable feedback which ultimately contributes to the quality of the decision-making process.